Status and phase
Conditions
Treatments
About
This is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug (QPI-1007) will be given to all patients who participate.
This study will determine whether QPI-1007 is safe when it is injected into the eye. The study will also reveal if there are any side effects of the drug and how long it takes for the body to clear the drug.
Full description
Patients will be enrolled according to one of two sets of criteria designated as Stratum I and Stratum II.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Stratum I (Chronic Optic Nerve Atrophy) Inclusion Criteria:
Key Stratum I (Chronic Optic Nerve Atrophy) Exclusion Criteria:
Enrollment is now closed in Stratum I.
Key Stratum II (Acute NAION) Inclusion Criteria:
Key Stratum II (Acute NAION) Exclusion Criteria:
Enrollment in Stratum II is still open.
48 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal